Skip to main content
OpenTrials

Clinical trial condition

Hematological Malignancies

Explore clinical trials studying Hematological Malignancies. Study availability and eligibility vary by location and protocol.

102 public trials 22 recruiting studies
Refine in advanced search Browse all conditions

Hematological Malignancies trial results

Completed

Expanded Access of Omidubicel, for Allogeneic Transplantation in Patients With Hematological Malignancies

NCT04260698

Conditions
Hematologic Diseases, Hematologic Neoplasms, Hematological Malignancies, +3 more
Locations
  • UCLA Los Angeles, California, United States
  • Stanford University Cancer Institute Palo Alto, California, United States
  • Loyola University, Cardinal Bernardin Cancer Center Maywood, Illinois, United States
  • University of Minnesota Masonic Cancer Center Minneapolis, Minnesota, United States
View Trial Details
Completed

Stem Cell Transplantation With NiCord® (Omidubicel) vs Standard UCB in Patients With Leukemia, Lymphoma, and MDS

NCT02730299

Conditions
Acute Leukemia, Acute Lymphoblastic Leukemia (ALL), Acute Myelogenous Leukemia (AML), +27 more
Locations
  • UCLA Los Angeles, California, United States
  • City of Hope Los Angeles, California, United States
  • Stanford University Cancer Institute Palo Alto, California, United States
  • UC San Diego Moores Cancer Center San Diego, California, United States
View all 52 locations
View Trial Details
Completed

A Study of Pembrolizumab/Vibostolimab (MK-7684A) in Relapsed/Refractory Hematological Malignancies (MK-7684A-004, KEYVIBE-004)

NCT05005442

Conditions
Hematologic Diseases, Hematologic Neoplasms, Hematological Malignancies, +3 more
Locations
  • City of Hope Comprehensive Cancer Center-Hematology ( Site 0024) Duarte, California, United States
  • University of Colorado Anschutz Medical Campus-The Center for Cancer and Blood Disorders ( Site 0021 Aurora, Colorado, United States
  • University of Chicago Medical Center ( Site 0005) Chicago, Illinois, United States
  • Henry Ford Hospital ( Site 0003) Detroit, Michigan, United States
View all 65 locations
View Trial Details
Completed

Establish the PK of Belinostat in Patients With Wild-type, Heterozygous, and Homozygous UGT1A1*28 Genotypes

NCT02680795

Conditions
Hematologic Diseases, Hematologic Neoplasms, Hematological Malignancies, +4 more
Locations
  • John Wayne Cancer Institute @ Providence Saint John's Health Center Santa Monica, California, United States
  • The Oncology Institute of Hope and Innovation Whittier, California, United States
  • Gabrail Cancer Center Research Canton, Ohio, United States
View Trial Details
Completed

Safety, Tolerability and Pharmacokinetics Study of KPG-818 in Hematological Malignancies Subjects

NCT04283097

Conditions
Hematologic Diseases, Hematologic Neoplasms, Hematological Malignancies, +3 more
Locations
  • UC Davis Comprehensive Cancer Center Sacramento, California, United States
  • BRCR Global - USA Plantation, Florida, United States
  • Norton Cancer Institute Louisville, Kentucky, United States
  • Henry Ford Health System - Hemophilia and Thrombosis Treatment Center Detroit, Michigan, United States
View Trial Details

Related conditions